Enterococcus: Difference between revisions
From IDWiki
Enterococcus
(→) |
(→) |
||
| Line 20: | Line 20: | ||
* ''E. casseliflavus'' |
* ''E. casseliflavus'' |
||
=== Resistance === |
=== Vacomycin Resistance === |
||
* Vancomycin binds to d-Ala-d-Ala pentapeptids, interfering with cell wall synthesis |
* Vancomycin binds to d-Ala-d-Ala pentapeptids, interfering with cell wall synthesis |
||
* '''VanA''': most common. Mutation to d-Ala-d-Lac, leading to high resistance to glycopeptides. |
* '''VanA''': most common. Mutation to d-Ala-d-Lac, leading to high resistance to glycopeptides. |
||
Revision as of 21:21, 19 January 2020
Background
Microbiology
- Facultative anaerobic, non-spore-forming, gamma-hemolytic, Gram positive diplococci
- Commensal gut flora
- Increasing antibiotic resistance
Species
- E. faecalis
- More common (90-95%)
- More commonly genitourinary source
- More susceptible to antibiotics
- E. faecium
- Less common (5-10%)
- More commonly gastrointestinal source
- Less susceptible to antibiotics
- Most common VRE
- E. gallinarum
- E. casseliflavus
Vacomycin Resistance
- Vancomycin binds to d-Ala-d-Ala pentapeptids, interfering with cell wall synthesis
- VanA: most common. Mutation to d-Ala-d-Lac, leading to high resistance to glycopeptides.
- VanB: more common in E. faecium in Australia
- VanC: chromosomal resistance on E. gallinarum and E. casseliflavus
Management
VRE
- Daptomycin, doxycycline, linezolid, tedizolid, oritavancin, quinupristin-dalfopristin (for E. faecium)
References
- ^ James H. Jorgensen, Sharon A. Crawford, Cynthia C. Kelly, Jan E. Patterson. In VitroActivity of Daptomycin against Vancomycin-Resistant Enterococci ofVarious Van Types and Comparison of Susceptibility TestingMethods. Antimicrobial Agents and Chemotherapy. 2003;47(12):3760-3763. doi:10.1128/aac.47.12.3760-3763.2003.
